Eytan M. Stein, MD: Enasidenib Shows “Encouraging” Efficacy in IDH2-Mutated AML

Treatment with the IDH2 inhibitor enasidenib was well-tolerated and led to an “impressive” response rate in patients with relapsed/refractory IDH2-mutated acute myeloid leukemia. Dr. Stein discusses results of the phase I/II trial.

SHARE